Ampio Pharmaceuticals, Inc. (AMPE) News
Filter AMPE News Items
AMPE News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest AMPE News From Around the Web
Below are the latest news stories about AMPIO PHARMACEUTICALS INC that investors may wish to consider to help them evaluate AMPE as an investment opportunity.
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on TuesdayIt's time to dive into the biggest pre-market stock movers as we check out all of the hottest trading news for Tuesday morning! |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on FridayIt's the final day of trading this week and we're starting it with a breakdown of the biggest pre-market stock movers on Friday morning! |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on ThursdayIt's time for a breakdown of the biggest pre-market stock movers as we check out all of the hottest news on Thursday morning! |
Presenting on the Emerging Growth Conference 64 Day 2 on November 2 Register NowMIAMI, Nov. 01, 2023 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 64th Emerging Growth Conference on November 1st and 2nd, 2023. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the conference here. Submit Questions for any of the presenting |
Ampio Pharmaceuticals to Present at the Emerging Growth ConferenceAmpio Pharmaceuticals, Inc. (NYSE American: AMPE) (the "Company), a pre-revenue stage biopharmaceutical company focused on development of a potential treatment for osteoarthritis as part of its OA-201 program, today announced that its CEO, Michael A. Martino will present in the Emerging Growth Conference on Thursday, November 2, 2023, at 1:10 pm ET. |
Ampio Selects Ascendia Pharmaceuticals, Inc. to Provide CDMO Services to Support Clinical Development of OA-201Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) (the "Company), a pre-revenue stage biopharmaceutical company focused on development of a potential treatment for osteoarthritis as part of its OA-201 program, today announced that it has selected Ascendia Pharmaceuticals, Inc. ("Ascendia") to provide services to support the clinical development of OA-201, a novel therapeutic for the treatment of symptomatic osteoarthritis pain. OA-201 consists of a natural metabolite, formulated as an injectable |
Presenting on the Emerging Growth Conference 63 Day 2 on October 5 Register NowMIAMI, Oct. 04, 2023 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of Day 2 of the 63rd Emerging Growth Conference on October 5th, 2023. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the conference here. Submit Questions for any of the presenting |
Ampio Pharmaceuticals Announces Reverse Stock SplitAmpio Pharmaceuticals, Inc. (NYSE American: AMPE) (the "Company") today announced that its Board of Directors has approved a 20-to-1 reverse stock split of the Company's common stock. The reverse stock split will become effective at 4:01pm ET on September 11, 2023. The Company's common stock is expected to begin trading on a split-adjusted basis on the NYSE American under the same symbol AMPE when the market opens on September 12, 2023 with the new CUSIP number 03209T307. |
Ampio Pharmaceuticals Announces Series D Preferred Stock Dividend to its Holders of Common StockAmpio Pharmaceuticals, Inc. (NYSE American: AMPE) (the "Company") today announced that its Board of Directors declared a dividend of one one-thousandth of a share of newly designated Series D Preferred Stock, par value $0.0001 per share, for each outstanding share of the Company's common stock held of record as of 5:00 p.m. Eastern Time on June 8, 2023. The shares of Series D Preferred Stock will be distributed to such recipients at 5:00 p.m. Eastern Time on June 8, 2023. Shares of Series D Pref |
AMPIO PHARMACEUTICALS ISSUES LETTER TO STOCKHOLDERSAmpio Pharmaceuticals, Inc. (NYSE American: AMPE) (the "Company") today released the following letter to stockholders from its Chairman, Kevin Buchi and Chief Executive Officer, Mike Martino. |